Poseida Therapeutics Inc (NAS:PSTX)
$ 3.46 0.54 (18.49%) Market Cap: 335.37 Mil Enterprise Value: 156.25 Mil PE Ratio: 0 PB Ratio: 2.69 GF Score: 35/100

Poseida Therapeutics Inc at HC Wainwright Cell Therapy Virtual Conference Transcript

Feb 28, 2023 / 04:00PM GMT
Release Date Price: $5.69 (-0.70%)
Arthur He
H.C. Wainwright & Co., LLC - Analyst

Good morning, and thanks for joining us at H.C. Wainwright's Cell Therapy Conference to have a conversation with Mr. Mark Gergen, the Chief Executive Officer of Poseida Therapeutics. Poseida is a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies to treat cancers and the rare genetic diseases.

The company is leveraging its proprietary platforms, including piggyBac, Cas-CLOVER, and the nanoparticle delivery technologies for pipeline development. Poseida currently has two clinical-stage allo CAR-T candidates and a number of preclinical in vivo gene therapy programs.

To discuss these programs and to learn about the company's development strategy in 2023 and beyond, I'd like to invite Mark to this fireside chat. Good morning, Mark.

Mark Gergen
Poseida Therapeutics, Inc. - CEO

Good morning, Arthur. Thanks for having us at the conference today.

Arthur He
H.C. Wainwright & Co., LLC - Analyst

Yeah, glad to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot